Figure 5

AD-MSCs biodistribution and histological study of peripheral organs. A, B) Migration and implantation of AD-MSCs after IV injection were studied in the ischemic brain by either MRI or immunofluorescence at 14 d. C) The presence of AD-MSCs administered to treated groups was checked in peripheral organs: liver, lungs and spleen at 14 d by DiI staining and also by co-labeling with CD11b/c (detail). D) H&E staining was used to study possible tumor formation in the kidney, liver, lung or spleen at 3 months after AD-MSCs administration (scale bars = 20 μm) (n = 5 per group).